Aquablation, HoLEP Provide Unique Benefits for Men With Benign Prostate Hyperplasia
By Lori Solomon HealthDay Reporter
TUESDAY, June 4, 2024 -- For men with benign prostate hyperplasia, aquablation provides temporary benefits for ejaculation and continence at three months, while holmium laser enucleation of the prostate (HoLEP) has superior operation time, safety profile, and volumetric results, according to a study published online May 9 in the World Journal of Urology.
Jakob Michaelis, from the Medical Centre-University of Freiburg in Germany, and colleagues compared the outcomes of aquablation (16 patients) and HoLEP (24 patients) among men with benign prostate hyperplasia.
The researchers found that HoLEP was associated with shorter operation time (59.5 versus 87.2 minutes) and led to better prostate volume reduction over all timepoints. Aquablation's results were better regarding ejaculatory and continence function at three months. However, there were no significant differences between the groups beyond three months for erectile, ejaculatory, continence function, and lower urinary tract symptom reduction. Clavien Dindo grade ≥3b complications were seen in six patients in the aquablation group versus one patient in the HoLEP group.
"We can conclude that both procedures have their specific strengths and that to offer a broad range of different procedures might give clinicians the opportunity to offer each patient the procedure which suits best their individual priorities and objectives," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Benign Prostatic Hyperplasia Risk Increased for Patients With Chronic Prostatitis
WEDNESDAY, April 3, 2024 -- Patients with chronic prostatitis (CP) have an increased risk for developing benign prostatic hyperplasia (BPH), according to a study published online...
Disparities in Transgender Prostate Screening Uptake Driven by Clinicians
FRIDAY, Feb. 23, 2024 -- Clinician recommendations are the most significant factor in driving prostate-specific antigen (PSA) screening in transgender women, according to a study...
Risk for Benign Prostatic Hyperplasia Increased for Patients With Gout
WEDNESDAY, Jan. 31, 2024 -- Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.